138 results about "Advanced stage" patented technology

The present invention discloses a control method and apparatus of resonant converter with low power loss at light load and standby. Based on the frequency response and loading condition of the resonant tank of a resonant converter, adjusts the switching frequency and the switching duty cycle to have a stable output voltage. Perform zero voltage switching and obtain higher converting efficiency by using the energy transfer in the resonant tank of the resonant type converter. Also have higher converting efficiency by combining with synchronize-rectify. Including: a resonant type converter, a controller of resonant type converter, and a regulated voltage mode (frequency modulation hybrid pulse width modulation, FMHYPWM) controller, and if the system specification require, a power factor correction or a double voltage rectifier circuit may be used in the advanced stage of the resonant type converter. The out put rectifier of the resonant type converter may be changed to a synchronized-rectifier.

Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein.

Compositions and methods for treating type 2 diabetes and its sequelae by intravenous or subcutaneous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly one or more anti-diabetic agents to human subjects are disclosed herein. The composition of the present invention may be used to: (i) treat patients with diabetes in advanced stages with evidence of any or all encephalopathy, retinopathy, nephropathy, pancreatitis or neoplasias; (ii) treat patients with diabetic disease status without symptomatic or pathologic evidence of associated sequelae but requiring better glycemic control than that offered by standard of care anti-diabetic; and (iii) patients with objective signs or symptoms of sequelae from diabetes of anti-diabetic drugs. One three-drug combination of the present invention includes a slow release PLGA-curcumin and an oral gliptin (DPP-4)-inhibitor or any incretin-mimetic and metformin.

A method and apparatus for combustion of a fuel in which a first-stage fuel and a first-stage oxidant are introduced into a combustion chamber and ignited, forming a primary combustion zone. At least about 5% of the total heat output produced by combustion of the first-stage fuel and the first-stage oxidant is removed from the primary combustion zone, forming cooled first-stage combustion products. A portion of the cooled first-stage combustion products from a downstream region of the primary combustion zone is recirculated to an upstream region of primary combustion zone. A second-stage fuel is introduced into the combustion chamber downstream of the primary combustion zone and ignited, forming a secondary combustion zone. At least about 5% of the heat from the secondary combustion zone is removed. In accordance with one embodiment, a third-stage oxidant is introduced into the combustion chamber downstream of the secondary combustion zone, forming a tertiary combustion zone.

A state of progression in an individual of a disease or treatment having motion symptoms is determined. A time series of accelerometer data is obtained from an accelerometer worn on an extremity of the person, over an extended period during everyday activities of the person. The accelerometer data is processed to produce a plurality of measures of kinetic state of the individual at a respective plurality of times throughout the extended period, each measure of kinetic state comprising at least one of: a measure for bradykinesia, and a measure for dyskinesia. A measure of dispersion of the measures of kinetic state is determined. An output is generated, indicating that motion symptoms are at an initial stage if the measure of dispersion is less than a threshold, or indicating that motion symptoms are at an advanced stage if the measure of dispersion is greater than the threshold.

The invention relates to the technical field of medical molecular biology and provides a method for detecting the serum marker of pancreatic cancer. The pancreatic cancer has high grade malignancy, difficult early diagnosis and poor prognosis, and the pancreatic cancer also lacks really effective solution, with surgical resection as the only therapeutic method to prolong survival period. Unfortunately, most of pancreatic cancer patients are in the advanced stage (TNM belongs to III and IV stages) and miss the surgical option. The invention aims at providing a method for detecting the serum marker of pancreatic cancer and applying the method to early diagnosis of pancreatic cancer and clinical judgment of laparotomy indication. The study proves that in the invention, the expression level of miR-196a in the serum is closely related to the postoperative survival period of pancreatic cancer; the study later proves that the relative expression abundance of miR-196a can well distinguish resectable pancreatic cancer (TNM belongs to I and II stages) from pancreatic cancer in advanced stage (TNM belongs to III and IV stages), so the method in the invention can be used for detecting the serum marker microRNA-196a of pancreatic cancer, and the method further has the advantages of convenient detection, good sensitivity and high accuracy.

Provided herein is a method for diagnosing/prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

The invention relates to a preparation method of a medical knee joint cruciate ligament, the steps mainly include that: the silk with the high quality is firstly selected to calculate the number of the weaving silk according to the biomechanics of the ligament, the silk is evenly divided into three parts to be braided and woven in the long strip cable-shaped silk cruciate ligament, and the medical knee joint cruciate ligament can be prepared by degumming, drying, silk protein fiber-collagen compound shaping and other steps. The invention has the advantages of convenient production, low cost and so on, when in use, the transplantation operation is simple, convenient, safe and reliable, etc. As the silk protein fiber, after the removal of sericin, has good mechanical properties and biocompatibility, the invention can bear the protection functions of knee joint stabilization, load conduction and articular cartilage of the natural cruciate ligament at the early stage of the transplantation, at the same time, the invention can support the cell growth and blood vessel growth at the advanced stage of the transplantation and be gradually degraded and absorbed along with the growth of the self-tissue and the regeneration of the cruciate ligament, so the invention provides a new choosing path for the treatment of the patients with the seriously damaged and apraxia knee joint cruciate ligament.

The invention relates to a preparation method of a medical knee joint meniscus, the steps mainly include that: silk with the high quality is firstly selected to be crocheted into a silk meniscus which takes a shape of wedge, the outer edge of the silk meniscus is thicker than the inner edge, and the medical knee joint meniscus can be prepared by degumming, drying, silk protein fiber-collagen compound shaping and other steps. The invention has the advantages of convenient production, low cost and so on, when in use, the transplantation operation is simple, convenient, safe and reliable, the tolerance of patients is good and the immunogenicity is small. As the silk protein fiber after the removal of sericin has good mechanical properties and biocompatibility, the invention can bear the functions of knee joint stabilization, load conduction, articular cartilage protection and lubrication of the natural meniscus at the early stage of the transplantation, at the same time, the invention has the function of a tissue engineering scaffold, and can support the cell growth and blood vessel growth at the advanced stage of the transplantation and be gradually degraded and absorbed along with the regeneration of the real natural meniscus, so the invention provides a new choosing path for the treatment of the patients with the seriously damaged and apraxia knee joint meniscus.

A new combined index of structure and function (CSFI) for staging and detecting glaucomatous damage is provided. An observational study including 333 glaucomatous eyes (295 with perimetric glaucoma and 38 with preperimetric glaucoma) and 330 eyes of healthy subjects is described. All eyes were tested with standard automated perimetry (SAP) and spectral domain optical coherence tomography (SDOCT) within 6 months. Estimates of the number of retinal ganglion cells (RGC) were obtained from SAP and SDOCT and a weighted averaging scheme was used to obtain a final estimate of the number of RGCs for each eye. The CSFI was calculated as the percent loss of RGCs obtained by subtracting estimated from expected RGC numbers. The performance of the CSFI for discriminating glaucoma from normal eyes and the different stages of disease was evaluated by receiver operating characteristic (ROC) curves. The mean CSFI, representing the mean estimated percent loss of RGCs, was 41% and 17% in the perimetric and pre-perimetric groups, respectively (P<0.001). They were both significantly higher than the mean CSFI in the normal group (P<Q.0( )1). The CSFI had larger ROC curve areas than isolated indexes of structure and function for detecting perimetric and preperimetric glaucoma and differentiating among early, moderate and advanced stages of visual field loss. An index combining structure and function performed better than isolated structural and functional measures for detection of perimetric and preperimetric glaucoma as well as for discriminating different stages of the disease.

The invention discloses a medicine for treating primary hepatic carcinoma. The medicine is prepared from the following medicinal raw materials: codonopsis pilosula, astragalus membranaceus, human placenta, radix paeoniae alba, fructus lycii, radix bupleuri, fingered citron, silybum marianum, lysimachia christinae hance, corn stigma, pericarpium citri reticulatae, rhizoma atractylodis macrocephalae, fructus aurantii, angelica sinensis, corydalis tuber, safflower carthamus, salviae miltiorrhizae, turtle shell, oldenlandia diffusa, sculellaria barbata, selfheal, dandelion, edible tulip, pericarpium citri reticulatae viride, kelp, myrrh and licorice root. The medicine is prepared from a prescription of pure traditional Chinese medicinal materials, has small toxic and side effect, and can be used for improving the living quality of patients with primary hepatic carcinoma in middle and advanced stage to prolong the lives of patients and curing early primary hepatic carcinoma. The total effective rate of the medicine for treating primary hepatic carcinoma is 100 percent.

A synchronous pipeline design is provided that includes a first predetermined number of fetch logic sections, or “stages”, and a second predetermined number of execution stages. Instructions are retrieved from memory and undergo instruction pre-decode and decode operations during the fetch stages of the pipeline. Thereafter, decoded instruction signals are passed to the execution stages of the pipeline, where the signals are dispatched to other execution logic sections to control operand address generation, operand retrieval, any arithmetic processing, and the storing of any generated results. Instructions advance within the various pipeline fetch stages in a manner that may be independent from the way instructions advance within the execution stages. Thus, in certain instances, instruction execution may stall such that the execution stages of the pipeline are not receiving additional instructions to process. This may occur, for example, because an operand required for instruction execution is unavailable. It may also occur for certain instructions that require additional processing cycles. Even though instructions are not entering the execution stages, instructions may continue to enter the fetch stages of the pipeline until all fetch stages are processing a respective instruction. As a result, when normal instruction execution resumes within the execution stages of the pipeline, all fetch stages of the pipeline have been filled, and pre-decode and decode operations have been completed for those instructions awaiting the entry into the execution stages of the pipeline.

The invention discloses a drug for treating middle-advanced stage esophagus cancer, which comprises the following components in parts by weight: 20-30 parts of codonopsis pilosula, 10-15 parts of rhizoma atractylodis macrocephalae, 10-15 parts of orange peel, 20-30 parts of semen coicis, 20-30 parts of Chinese yam, 5-10 parts of liquorice, 10-15 parts of mangnolia officinalis, 10-15 parts of fructus aurantii, 10-15 parts of radix curcumae, 5-10 parts of bulbus fritillariae cirrhosae, 10-15 parts of allium macrostemon, 10-15 parts of fructus trichosanthis, 20-30 parts of radix paeoniae alba, 10-15 parts of agilawood, 10-15 parts of fingered citron, 10-15 parts of arisaema consanguineum schott, 10-15 parts of radix scrophulariae, 10-15 parts of pericarpium citri reticulatae, 10-15 parts of pinellia ternate, 5-10 parts of fructus amomi, 10-15 parts of inula flower, 10-15 parts of ruddle, 10-15 parts of lotus petiole, 5-10 parts of coptis chinensis, 10-15 parts of radix aucklandiae, 10-15 parts of radix aucklandiae, 10-15 parts of adenophora stricta, 20-30 parts of rehmannia glutinosa, 10-20 parts of ophiopogon japonicas, 10-20 parts of angelica sinensis, 10-15 parts of lalang grass rhizome, 20-30 parts of oldenlandia diffusa, 20-30 parts of sculellaria barbata, 1-5 parts of centipede, 5-10 parts of buthus martensi kirsch, 10-20 parts of salvia miltiorrhiza, 10-15 parts of fructus forsythia, 10-20 parts of manyleaf paris rhizome, 10-15 parts of peach kernel, 10-15 parts of flos carthami, 10-15 parts of frankincense and 10-15 parts of myrrh. The drug can achieve the purposes of regulating qi-flowing and eliminating phlegm for removing stasis, nourishing yin and engendering liquid for removing stasis, and promoting blood circulation to remove blood stasis; the effective rate can reach 66%.

The invention relates to a traditional Chinese medicine composition for curing cancers, which is characterized in that the composition is prepared by the following 34 kinds of raw materials by weight: 10-20 parts of angelica sinensis, 10-20 parts of rhizoma Atractylodis Macrocephalae, 10-20 parts of poria, 15-20 parts of ligusticum wallichii, 15-20 parts of radix bupleuri, 10-20 parts of white paeony roots, 10-20 parts of root barks of the peony tree, 18-25 parts of isatis roots, 15-20 parts of roots of red-rooted salvia, 18-25 parts of astragalus membranaceus, 18-25 parts of fructus lycii, 18-25 parts of fleece-flower roots, 15-20 parts of black sesames, 15-20 parts of red phaseolus beans, 18-25 parts of oriental wormwood, 10-20 parts of lilac, 10-20 parts of white lilac, 15-20 parts of muskmelon pedicel, 15-20 parts of waxgourd peel and the like. The traditional Chinese medicine composition for curing cancers has the advantages of having obvious effects on improving common nutritiveindexes of patients, also having obvious effects on improving the common nutritive indexes of the other patients in the advanced stage, and having remarkable effects on curing tumors.

The invention relates to a colloidal gold testing card for testing sjogren's syndrome alpha-fodrin autoantibody. The testing card comprises orderly arranged components of, from left to right: a sample pad, glass fiber, a nitrocellulose membrane, and absorbent paper. Recombinant protein G labeled by nano-sized colloidal gold is applied on the glass fiber. Macromolecular-protein-coupled alpha-fodrin epitope polypeptide and recombinant protein G resistant antibody are fixed on the nitrocellulose membrane, wherein the sequence of alpha-fodrin epitope polypeptide is represented by SEQ ID NO: 1. Recombinant protein G resistant antibody fixed on the end close to the absorbent paper forms a control line, and macromolecule-protein-coupled alpha-fodrin epitope polypeptide fixed on the end close to the glass fiber forms a test line. The colloidal gold testing card provided by the present invention has advantages of easy preparation and quick testing. With the testing card, no professional technicist or expensive equipment is required. The testing card is suitable for large batch testing, and is suitable to be used in primary areas. The testing card has auxiliary diagnosis functions on early-stage sjogren's syndrome, and intermediate and advanced stage sjogren's syndromes.

The invention discloses an intermediate-advanced stage cancer imaging detecting system and an intermediate-advanced stage cancer imaging detecting method based on the quantum superstring engine, mainly used for overcoming the defect that the traditional medical device can not efficiently, safely, rapidly and comprehensively detect the cancer cell spreading area of a cancer patient. The intermediate-advanced stage cancer imaging detecting system comprises a quantum light emission source, an optical splitter, a convex lens, a light filter group, a detection unit, an image processing unit and a display. The intermediate-advanced stage cancer imaging detecting method comprises the steps that orthogonal polarized photons generated by the quantum light emission source pass through the optical splitter, and then are transmitted in two paths; one path of the orthogonal polarized photons irradiates the body of the patient through the convex lens and light filters, penetrates through the body and then is received by a detector, and the other path of the orthogonal polarized photons directly passes through the light filters, and are received by another detector; the detection unit carries out combined measurement on the photons detected by the two detectors, and outputs a detection result to the image processing unit, the image processing unit draws a diffusion area imaging picture of cancer cells in the body of the patient, and the diffusion area imaging picture is displayed by the display. With the adoption of the intermediate-advanced stage cancer imaging detecting system and the intermediate-advanced stage cancer imaging detecting method, the diffusion area imaging picture of the cancer cells can be obtained, and thus a basis is provided for the treatment and research on the cancer patient.

The invention discloses application of a circ_SLC7A5 molecular marker in blood in diagnosing esophageal squamous carcinoma and prognosis, and relates to discovery, detection and application of the circ_SLC7A5 molecular marker. A specific detection primer for real-time quantitative PRC is designed and synthesized. Circ_SLC7A5 in the blood can serve as a plasma marker for ESCC patients, aiming at the status quo that a target group of people have poor compliance on esophagus cancer endoscope screening, and most of esophageal squamous carcinoma patients with definite diagnosis in clinic are in themiddle and advanced stage, ideal molecular early-warning signals are found out in the esophagus squamous cell canceration process, endoscopy is targetedly carried out, the pathology is conformed, sothat the pain of the patients is alleviated, excessive medical treatment is avoided, and medical resources are saved.

The invention relates to the field of drug formulas, in particular to a traditional Chinese drug for treating diabetic peripheral neuropathy. The traditional Chinese drug is characterized by being prepared from the following raw material herbs by weight percentage: 7-9% of caulis spatholobi, 4-7% of phryma leptostachya, 5-8% of hematoxylon, 4-6% of smallfruit fig aerial root, 6-8% of radices lithospermi, 4-7% of herba leonuri, 4-7% of short-pedicel aconite root, 2-5% of asarum, 4-6% of silvervine tea, 3-6% of folium artemisiae argyi, 5-8% of Eclipta prostrata, 4-8% of multiflora rose fruit, 3-6% of Commelina diffusa, 6-10% of spina gleditsiae, 4-7% of gorgon fruit, 3-5% of radix asparagi and 3-6% of rhizoma pinelliae preparata. The raw material herbs are soaked in water and decocted, and residues are removed to obtain a filter liquor. The traditional Chinese drug is high in curative effect of treating diabetic peripheral neuropathy, free of toxic and side effects and suitable of treating diabetic peripheral neuropathy in the early stage or in the advanced stage.

The invention provides a whole nutrient formula food for tumors. The whole nutrient formula food is prepared from calcium beta-hydroxy-beta-methylbutyrate, a broccoli seed extract, carbohydrate, protein, fat microcapsule powder, dietary fibers, a mineral compound, a vitamin compound, immunity nutrients and appropriate auxiliary materials. The energy density of the whole nutrient formula food is greater than 1.2kcal/mL, and the whole nutrient formula food can provide comprehensive reasonable nutrient support for patients during perioperative periods, radiotherapy or chemotherapy periods and advanced-stage palliative treatment, synergistically exert effects in the respects of enhancing immunity, controlling inflammation disease development and adjusting and controlling tumor development, caneffectively protect the barriering functions of the gastrointestinal tract mucosa of tumor patients during the period of receiving treatment, and can relieve side effects during treatment course.